Finerenone in FSGS: What the FIND-CKD Subgroup Shows
In a prespecified FIND-CKD FSGS subgroup (n=215), finerenone slowed total eGFR decline by 1.3 mL/min/1.73 m² per year versus placebo and lowered proteinuria by 41% at 12 months. The kidney composite favored finerenone but was not statistically conclusive. This is not a dedicated FSGS trial.